Search for Cases

Case Details

Case Code: LDEN136
Case Length: 17 Pages 
Period: 2018   
Pub Date: 2019
Teaching Note: Available
Price: Rs.500
Organization : Dr. Reddy’s Laboratories Ltd
Industry :Pharmaceuticals
Countries : India; United States; Germany
Themes: 
Case Studies  
Business Strategy
Marketing
Finance
Human Resource Management
IT and Systems
Operations
Economics
Leadership & Entrepreneurship

Dr. Reddy`s Laboratories: Challenges ahead for Erez Israeli

 
<<Previous Page

EXCERPTS

THE NEW LEADER

 

In March 2018, Mukherjee retired as the Chief Operating Officer, a position he had held since 2014. He played an instrumental role in the growth of the company, especially during the acquisition of Roche’s API Business in Mexico and the acquisition of Dow pharma’s UK-based small molecule business. He also led the strategic alliance with GSK for Emerging Markets. He served as the President of PSAI and as the President of Developing Businesses of DRL. Mukherjee earned the reputation of being a seasoned marketer with superior technical knowledge, having completed his graduation in Chemical Engineering from the Indian Institute of Technology, Kharagpur...

 
Leadership and Entrepreneurship Case Studies | Case Study in Management, Operations, Strategies, Business Environment, Case Studies
or
Leadership and Entrepreneurship Case Studies | Case Study in Management, Operations, Strategies, Business Environment, Case Studies
or
PayPal (11 USD)

 

FUTURE IS COMPLEX

Analysts believed that there might not be a simple solution to the price control and with the US Generic industry showing clear signs of hitting a plateau in terms of sales, Israeli would be tested on the quality of the products. He along with the management council needed to build a culture of compliance, especially on the manufacturing and quality sides, in order to steer clear of the surprise audits. Industry analysts felt Israeli along with the management council needed to create a culture of transparency and compliance...
 

EXHIBITS

Exhibit I: Dr. Reddy’s Brand’s Promises
Exhibit II: Revenue Mix by Segment
Exhibit III:Brief Note on the Channel Consolidation in US
Exhibit IV: DRL - Revenues of the Generic Business from North America.
Exhibit V: Top Pharmaceutical Corporations by US Market in 2016
Exhibit VI: Revenue data in Russia
Exhibit VII: Revenue in Global Generics India
Exhibit VIII: Employee Costs as per the Latest Profit & Loss Account Available
Exhibit IX: Brief Snapshot of Selected Indian Pharma companies